BioXcel Therapeutics, Inc. (BTAIQ): Cash & Equivalents
$28.41M
As of 2025-12-31
$12.84M
As of 2026-06-30
-47.3%
3-year compound annual growth
-33.2%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $28.41M | -4.8% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $29.85M | -54.2% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $65.22M | -66.3% | 2025-03-28, Balance as of period end |
| 2022-12-31 | $193.72M | -16.8% | 2024-03-22, Balance as of period end |
| 2021-12-31 | $232.97M | +9.3% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $213.12M | +557.2% | 2022-03-11, Balance as of period end |
| 2019-12-31 | $32.43M | -23.8% | 2021-03-12, Balance as of period end |
| 2018-12-31 | $42.56M | n/m | 2020-03-09, Balance as of period end |
| 2017-12-31 | $887.0K | n/a | 2019-03-12, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $28.41M | -4.8% |
| Polomar Health Services, Inc. (PMHS) | 2025-12-31 | $132.2K | n/m |
| Vaccinex, Inc. (VCNX) | 2024-12-31 | $1.11M | -27.9% |
| PMGC Holdings Inc. (ELAB) | 2024-12-31 | $3.98M | +19.8% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $24.03M | +20.6% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $11.28M | -90.7% |
| Lipella Pharmaceuticals Inc. (LIPO) | 2024-12-31 | $2.18M | -33.7% |
| Hyperion Defi, Inc. (HYPD) | 2025-12-31 | $6.44M | +203.7% |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | $40.99M | -41.3% |
Compare BTAIQ, PMHS, VCNX, ELAB side by side · Screen every company in Pharmaceutical Preparations ↗